Login

Saule Naureckas

ORCID: 0000-0002-5043-7417
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5070367905
Research Areas
  • Pregnancy and Medication Impact
  • Reproductive System and Pregnancy
  • Eosinophilic Esophagitis

Janssen (United States)
 2022

 Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database
OPENALEX - Publications 
Uma Mahadevan Saule Naureckas Ilia Tikhonov Yiting Wang Connie B. Lin and 2 more Anja Geldhof C. Janneke van der Woude

Summary Background Ustekinumab, a human immunoglobulin G1 monoclonal antibody that binds to and inhibits interleukin (IL)‐12/IL‐23, is indicated for multiple immune‐mediated diseases. Ustekinumab actively transported across the placenta theoretically could impact pregnancy outcomes. Limited data on outcomes with ustekinumab exposure are available. Aim To assess in patients exposed during Methods Cumulative medically confirmed ustekinumab‐exposed pregnancies from manufacturer's Global Safety...

10.1111/apt.16960 article EN Alimentary Pharmacology & Therapeutics 2022-05-12
 Su1799 - Pregnancy Outcomes in Women Exposed to Ustekinumab
OPENALEX - Publications 
Uma Mahadevan Saule Naureckas Bhawna Sharma Ilia Tikhonov Philippe Szapary and 2 more Christopher Busse Alexa B. Kimball

10.1016/s0016-5085(18)32145-0 article EN Gastroenterology 2018-05-01
Coming Soon ...